BioSpace News Archive

According to the new research, Brain Machine Interfaces & Neuromodulation: Impact Assessments, Vendor Positioning & Market Forecasts 2019-2030, BMIs will expand beyond pure experimental medical use cases, with strong consumer uses developing.

Vor Biopharma announced a publication in the scientific journal Proceedings of the National Academy of Sciences titled “Gene-Edited Stem Cells Enable CD33-Directed Immune Therapy for Myeloid Malignancies.” The research describes the successful editing of HSCs that are engineered to be selectively deficient in the myeloid lineage antigen CD33.

Exfoliating your skin is an important part of any dermal care routine.

EUSA Pharma announces that the Principal Investigators from two studies of QARZIBA®▼1,2 in the treatment of high-risk neuroblastoma will present new data at the 2019 American Society of Clinical Oncology Annual Meeting to be held May 31 through June 4, 2019 in Chicago, IL.

Leica Biosystems, the global leader in pathology workflow solutions, announced that it has received clearance from the U.S. Food and Drug Administration to market its Aperio AT2 DX System for clinical diagnosis in the U.S.

Picosun Group, the global provider of AGILE ALD™ thin film coating solutions, continues its breakthrough into healthcare industries by supplying ALD technology to produce bioactive coatings on surgical implants at a major, leading manufacturer.

Boehringer Ingelheim and Gubra announce a second collaboration and license agreement for the development of novel poly-agonist peptides to treat obesity.

Hospital Performance Varies on Unnecessary Cesarean Sections, Early Elective Deliveries and Episiotomies

Sihuan Pharmaceutical Holdings Group Ltd., the largest cardio-cerebral vascular drug manufacturer in China’s prescription drug market, announced the third generation of EGFR inhibitor XZP-5809, a Category 1 innovative drug developed by the Group, has been granted drug clinical trial approval by the National Medical Products Administration of the PRC.

Passport’s owners select Evolent as Passport’s long-term financial and operating partner for the health plan joint venture.